Device Trial Radar · NCT06305208
A UK Registry for Metabolic and Bariatric Endoscopic Interventions
Last checked: Nov 20, 2026Latest source record: Mar 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Feb 1, 2024
Primary completion
Feb 1, 2034
Study completion Feb 1, 2039
Sponsor
- Lead sponsor
- Cleveland Clinic LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 12, 2024
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In the UK alone, obesity is a major health problem with more than one quarter of adults estimated to be obese. Obesity promotes the development of many serious diseases including diabetes, heart disease, kidney disease, and increased risk of some cancers. Patients living with obesity also suffer from significant symptoms that impact their life including shortness of breath, back pain, poor mobility, and poor mental health. Traditional methods to help lose weight include low calorie diets and increased exercise. These may be effective in the short-term, but due to powerful biological mechanisms they are hard to maintain over the long-term and most individuals are unable to achieve normal weight. This means many people may need bariatric surgery that is highly effective at lowering body weight, but it is associated with complications and not all patients will want or be able to undergo surgery. This has led to the development of many new obesity treatments that are completed with an endoscope. An endoscope is a thin flexible tube that has a camera at the end. It is inserted through the mouth and into the stomach and small bowel. There are various procedures that can be done at the time of endoscopy that have been shown to be effective with a low number of side-effects. These are still relatively new compared to more traditional treatments and only a small number of doctors can perform them within the UK. Due to these limitations, the aim of this registry is to obtain real-world information on the safety and effectiveness of these procedures across the UK. The investigators hope over time this will improve the knowledge of clinicians about treating obesity with endoscopy and support future access and funding to these treatments.
Conditions
- Obesity
- Diabetes Mellitus, Type 2
Interventions
Endoscopic gastric suturingDevice
Endoscopic suturing of the stomach to reduce volume and promote weight loss with either the Apollo Overstitch or Overstitch Sx system.
Endoscopic gastric plicationDevice
Endoscopic plication of the stomach to reduce volume and promote weight loss with either the POSE or Endomina system.
Revisional gastroplastyDevice
Endoscopic suturing or plication of the stomach among patients who have previously undergone gastroplasty, sleeve gastrectomy, or Roux-en-Y gastric bypass to restrict the stomach and promote weight loss
Transoral outlet reduction endoscopy (TORe)Device
Reduction of the size of the gastro-jejunal anastomosis among patients who have previously undergone Roux-en-Y gastric bypass to promote weight loss. A variety of techniques may be used alone or in isolation including suturing (Apollo Overstitch), plication (POSE), argon photocoagulation, and endoscopic submucosal resection/dissection.
Duodenal mucosal resurfacing (DMR)Device
Endoscopic ablation of the post-ampullary duodenal mucosal to enhance improvement in glycaemic control among patients with type 2 diabetes.
Intragastric balloon(s)Device
The insertion of an intragastric implant into the stomach, which is subsequently filled with air or water to promote weight loss. Several intragastric balloons are available including Allurion, Heliosphere, Obalon, Orbera, and Spatz.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total body weight loss percentage (TBWL%)Time frame: 6-months, 1-, 2-, 3-, 5-years
- Change in glycated haemoglobin (HbA1c; mmol/mol)Time frame: 6-months, 1-, 2-, 3-, 5-years
- Change in the number and dose of anti-diabetic medicationsTime frame: 6-months, 1-, 2-, 3-, 5-years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cleveland Clinic London
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.